AbbVie, Schizophrenia
AbbVie Tumbles After New Schizophrenia Drug Fails Two Trials
AbbVie Inc. shares fell the most in more than four years after two mid-stage trials of its drug to treat schizophrenia failed to meet their primary goal, a blow to the company’s $8.7 billion acquisition of Cerevel Therapeutics earlier this year.
Barchart on MSN4d
Are Wall Street Analysts Bullish on AbbVie Stock?With a market cap of $356.2 billion, North Chicago, Illinois-based AbbVie Inc. (ABBV) operates in the pharmaceutical sector.
AbbVie Inc. raised its full-year profit forecast as demand for its top-selling anti-inflammatory drugs, Rinvoq and Skyrizi, ...
The foundation donation will go toward construction of UChicago Medicine's $815 million freestanding cancer care center in ...
NORTH CHICAGO, Ill. — NORTH CHICAGO, Ill. — AbbVie Inc. (ABBV) on Wednesday reported third-quarter profit of $1.56 billion. On a per-share basis, the North Chicago, Illinois-based company said it had ...
AbbVie and Aliada Therapeutics have announced a definitive agreement under which AbbVie will acquire Aliada, a biotechnology ...
EMPOWER-1 and EMPOWER-2 Phase 2 clinical trials did not meet their primary endpoint Emraclidine was well-tolerated with an adverse event profile consistent with ...
EvolveImmune Therapeutics Inc., a Branford-based bioscience company developing therapeutics to overcome cancer cell ...
AbbVie (NYSE: ABBV) and EvolveImmune Therapeutics, an immuno-oncology company developing next-generation biotherapeutics to overcome the therapeutic challenges of cancer cell resistance to current ...
Chicago Tribune on MSN11d
UChicago Medicine receives $75M donation for new cancer hospital“We’re really excited and proud to have the opportunity to support University of Chicago Medicine and the South Side community in this way,” said Claudia Carravetta, vice president corporate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback